Trails Edge Capital Partners, LP — 13F Holdings & Portfolio

CIK 2077247 · latest 13F-HR filed 2026-08-14

Trails Edge Capital Partners, LP manages $629.9M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LBRX (7.85%), NRIX (6.06%), IMCR (5.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions and exited 4; 14 existing positions rose in reported value and 5 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$629.9M

Long-equity book

Holdings
35

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+13 / −4 / ↑14 / ↓5

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 50.3%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Apr 14, 2026.

Assets Under Management
$933.4M
Discretionary
$933.4M
Employees
7
Accounts
3
Address
3445 PEACHTREE ROAD NE
SUITE 900
ATLANTA, GA 30326
Phone
(770) 600-9010
Name Title / Status Ownership Type
DIAZ, MATTHEW, JAMES ControlCHIEF FINANCIAL OFFICER, CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
since Jan 2025
Less than 5%Individual
TRAILS EDGE CAPITAL PARTNERS, LLC ControlGENERAL PARTNER
since Oct 2024
Less than 5%Domestic Entity
YEHUDAI, ORTAV, DANIEL ControlPRINCIPAL
since Oct 2024
75% or moreIndividual

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Trails Edge Capital Partners, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 LB PHARMACEUTICALS INC LBRX 50180M108 $49.4M 7.85% 1,523,022 SH
2 NURIX THERAPEUTICS INC NRIX 67080M103 $38.2M 6.06% 1,573,220 SH
3 IMMUNOCORE HLDGS PLC IMCR 45258D105 $33.8M 5.36% 1,063,234 SH
4 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $30.5M 4.84% 1,514,000 SH
5 4D MOLECULAR THERAPEUTICS IN FDMT 35104E100 $29.6M 4.70% 2,227,917 SH
6 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $29.3M 4.65% 512,000 SH
7 DESIGN THERAPEUTICS INC DSGN 25056L103 $29.0M 4.60% 2,001,282 SH
8 XENON PHARMACEUTICALS INC XENE 98420N105 $26.6M 4.22% 440,000 SH
9 MIRUM PHARMACEUTICALS INC MIRM 604749101 $26.1M 4.15% 223,312 SH
10 INSMED INC INSM 457669307 $24.6M 3.90% 230,331 SH
11 CYTOKINETICS INC CYTK 23282W605 $24.5M 3.90% 288,089 SH
12 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $24.3M 3.85% 1,110,000 SH
13 NEUROGENE INC NGNE 64135M105 $22.5M 3.57% 714,885 SH
14 KAILERA THERAPEUTICS INC KLRA 482931102 $21.7M 3.44% 984,786 SH
15 REVOLUTION MEDICINES INC RVMD 76155X100 $21.7M 3.44% 115,750 SH
16 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $18.4M 2.92% 9,051,318 SH
17 INCYTE CORP INCY 45337C102 $17.6M 2.79% 155,000 SH
18 AVALO THERAPEUTICS INC AVTX 05338F306 $16.5M 2.62% 891,881 SH
19 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $14.6M 2.32% 750,000 SH
20 FAETH THERAPEUTICS INC FTH 81728A207 $12.9M 2.05% 515,335 SH
21 X4 PHARMACEUTICALS INC XFOR 98420X202 $12.0M 1.91% 2,571,478 SH
22 OPUS GENETICS INC IRD 67577R102 $11.3M 1.79% 2,743,658 SH
23 SOL-GEL TECHNOLOGIES LTD SLGL M8694L137 $10.3M 1.64% 139,445 SH
24 AURA BIOSCIENCES INC AURA 05153U107 $10.2M 1.63% 1,443,333 SH
25 CENTURY THERAPEUTICS INC IPSC 15673T100 $10.1M 1.61% 4,134,969 SH
26 INVENTIVA SA IVA 46124U107 $10.0M 1.60% 2,657,997 SH
27 CAMP4 THERAPEUTICS CORP CAMP 13463J101 $8.4M 1.34% 1,932,937 SH
28 ALTIMMUNE INC ALT 02155H200 $8.1M 1.28% 2,660,000 SH
29 MINERVA NEUROSCIENCES INC NERV 603380205 $7.9M 1.25% 1,419,000 SH
30 PROMIS NEUROSCIENCES INC PMN 74346M505 $7.3M 1.16% 557,103 SH
31 ONKURE THERAPEUTICS INC OKUR 68277Q105 $6.6M 1.04% 1,438,456 SH
32 FORTE BIOSCIENCES INC FBRX 34962G208 $5.8M 0.92% 273,181 SH
33 RESEARCH ALLIANCE CORP III RACC G75226103 $5.3M 0.85% 500,000 SH
34 VTV THERAPEUTICS INC VTVT 918385204 $3.2M 0.51% 85,192 SH
35 IMAGENEBIO INC IMA 45175G207 $1.7M 0.26% 282,004 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $629.9M 35 0002077247-26-000004
2026-03-31 2026-05-15 $436.5M 27 0002077247-26-000003
2025-12-31 2026-02-17 $404.7M 23 0002077247-26-000002
Filer Information
Address
3445 PEACHTREE ROAD NE, SUITE 900
ATLANTA, GA 30326
Phone
(917) 657-2249
Filing Manager
Trails Edge Capital Partners, LP
ATLANTA, GA
Signatory
Matthew Diaz
Chief Compliance Officer